rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Carl Dockery

Director

Company insider

Files Form 4 as: Director, Aytu BioPharma; Director and 10% owner, CytoDyn.

Every Form 4 they filed

In numbers

Trades disclosed
102
Buys
4
Sells
1
Bought
$2.1M
Sold
$1,256
Companies
2
Companies where not an officer
2
First trade
6 Oct 2014
Last trade
28 Jul 2026
Last filed
30 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
AYTU Aytu BioPharmaDirector · Biotechnology · last 28 Jul 20262 buys · 1 sell
CytoDynDirector, 10% owner · last 18 Jun 20192 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
28 Jul 2026filed 30 Jul 2026AYTU Aytu BioPharmaBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
28 Jul 2026filed 30 Jul 2026AYTU Aytu BioPharmaBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
3 Oct 2025filed 7 Oct 2025AYTU Aytu BioPharmaBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
6 Nov 2024filed 8 Nov 2024AYTU Aytu BioPharmaBiotechnologySEC FORM 4 Code A—1,500 at $0.00filing
11 Aug 2023filed 15 Aug 2023AYTU Aytu BioPharmaBiotechnologySEC FORM 4 Code A—1,500 at $0.00filing
21 Dec 2022filed 23 Dec 2022AYTU Aytu BioPharmaBiotechnologySEC FORM 4 Code D—40,000 at $0.00filing
16 Apr 2021filed 16 Apr 2021AYTU Aytu BioPharmaBiotechnologySEC FORM 4 Code A—187,804 at $0.00filing
30 Dec 2020filed 20 Oct 2025AYTU Aytu BioPharmaBiotechnologySEC FORM 4 Sold$1,256209 at $6.01filing
18 Nov 2020filed 20 Oct 2025AYTU Aytu BioPharmaBiotechnologySEC FORM 4 Bought$9,20010,000 at $0.92filing
8 Jun 2020filed 17 Aug 2020AYTU Aytu BioPharmaoption or derivative · BiotechnologySEC FORM 4 Code A—40,000 at $0.00filing
18 Jun 2019filed 19 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code A—100,000 at $0.00filing
12 Jun 2019filed 14 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code D—75,000filing
12 Jun 2019filed 14 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code D—1,000,000filing
12 Jun 2019filed 14 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code A—1,000,000filing
12 Jun 2019filed 14 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code M—1,000,000 at $0.00filing
12 Jun 2019filed 14 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code D—33,333filing
12 Jun 2019filed 14 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code A—33,333filing
12 Jun 2019filed 14 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code M—33,333 at $0.00filing
12 Jun 2019filed 14 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code D—250,000filing
12 Jun 2019filed 14 Jun 2019CytoDynoption or derivativeSEC FORM 4 Code A—250,000filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care3
Not placed2

Buys in green, sells in red, by the company’s sector.

Related people

Vivian H. LiuDirector · Director at Aytu Biopharma, filing Form 4 there in the last year
Joshua R. DisbrowChief Executive Officer · Chief Executive Officer at Aytu Biopharma, filing Form 4 there in the last year
Jarrett DisbrowChief Business Officer · Chief Business Officer at Aytu Biopharma, filing Form 4 there in the last year
Ryan J. SelhornChief Financial Officer · Chief Financial Officer at Aytu Biopharma, filing Form 4 there in the last year
John Donofrio Jr.Director · Director at Aytu Biopharma, filing Form 4 there in the last year